| Dr Frederick Jones Tanenggee, MD | |
|
595 W Lake Mead Pkwy, Henderson, NV 89015-7015 | |
| (702) 565-1007 | |
| (702) 565-0836 |
| Full Name | Dr Frederick Jones Tanenggee |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 29 Years |
| Location | 595 W Lake Mead Pkwy, Henderson, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245284959 | NPI | - | NPPES |
| 9921 | Other | NV | STATE LICENSE |
| 1245284959 | Medicaid | NV |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 9921 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Medical Holdings Nevada Inc | 7416054622 | 286 |
News Archive
With the growing number of long-term lung cancer survivors, research is needed to identify and address cancer survivorship issues. One of the most common and debilitating symptoms among lung cancer patients is dyspnea, or shortness of breath. As most studies of dyspnea have reviewed patients with active lung cancer or immediately after treatment, the prevalence of dyspnea over the long-term once treatment has been completed is not well characterized.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
The British Society for Rheumatology publishes its latest clinical guideline in Rheumatology, the UK's key specialist journal in the sector. The new guideline updates and presents two previous guidelines into one set of evidence based recommendations on the vital safety aspects of prescribing biological therapies in inflammatory arthritis.
Researchers aimed to find a relationship between geographic variation in Medicare Part D spending and medication-taking behavior among patients with diabetes or heart failure.
› Verified 7 days ago
| Entity Name | Healthcare Partners Medical Group Coats Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487631917 PECOS PAC ID: 5991866303 Enrollment ID: O20100113000898 |
News Archive
With the growing number of long-term lung cancer survivors, research is needed to identify and address cancer survivorship issues. One of the most common and debilitating symptoms among lung cancer patients is dyspnea, or shortness of breath. As most studies of dyspnea have reviewed patients with active lung cancer or immediately after treatment, the prevalence of dyspnea over the long-term once treatment has been completed is not well characterized.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
The British Society for Rheumatology publishes its latest clinical guideline in Rheumatology, the UK's key specialist journal in the sector. The new guideline updates and presents two previous guidelines into one set of evidence based recommendations on the vital safety aspects of prescribing biological therapies in inflammatory arthritis.
Researchers aimed to find a relationship between geographic variation in Medicare Part D spending and medication-taking behavior among patients with diabetes or heart failure.
› Verified 7 days ago
| Entity Name | Intermountain Medical Holdings Nevada Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245997279 PECOS PAC ID: 7416054622 Enrollment ID: O20220214001765 |
News Archive
With the growing number of long-term lung cancer survivors, research is needed to identify and address cancer survivorship issues. One of the most common and debilitating symptoms among lung cancer patients is dyspnea, or shortness of breath. As most studies of dyspnea have reviewed patients with active lung cancer or immediately after treatment, the prevalence of dyspnea over the long-term once treatment has been completed is not well characterized.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
The British Society for Rheumatology publishes its latest clinical guideline in Rheumatology, the UK's key specialist journal in the sector. The new guideline updates and presents two previous guidelines into one set of evidence based recommendations on the vital safety aspects of prescribing biological therapies in inflammatory arthritis.
Researchers aimed to find a relationship between geographic variation in Medicare Part D spending and medication-taking behavior among patients with diabetes or heart failure.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Frederick Jones Tanenggee, MD 6355 S Buffalo Dr Fl 3, Las Vegas, NV 89113-2133 Ph: (702) 216-3346 | Dr Frederick Jones Tanenggee, MD 595 W Lake Mead Pkwy, Henderson, NV 89015-7015 Ph: (702) 565-1007 |
News Archive
With the growing number of long-term lung cancer survivors, research is needed to identify and address cancer survivorship issues. One of the most common and debilitating symptoms among lung cancer patients is dyspnea, or shortness of breath. As most studies of dyspnea have reviewed patients with active lung cancer or immediately after treatment, the prevalence of dyspnea over the long-term once treatment has been completed is not well characterized.
ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.
The British Society for Rheumatology publishes its latest clinical guideline in Rheumatology, the UK's key specialist journal in the sector. The new guideline updates and presents two previous guidelines into one set of evidence based recommendations on the vital safety aspects of prescribing biological therapies in inflammatory arthritis.
Researchers aimed to find a relationship between geographic variation in Medicare Part D spending and medication-taking behavior among patients with diabetes or heart failure.
› Verified 7 days ago
James B Gabroy, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1535 West Warm Spring Road, Suite 135, Henderson, NV 89014 Phone: 702-450-3385 Fax: 702-898-1699 | |
Dr. Poupak Ziaei, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2641 W Horizon Ridge Pkwy Ste 100, Henderson, NV 89052 Phone: 702-616-0091 Fax: 702-616-2329 | |
Dr. Jeannette Nee, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2865 Siena Heights Dr, Suite 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Wen Liang, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2621 W Horizon Ridge Pkwy, Suite 150, Henderson, NV 89052 Phone: 702-837-6368 Fax: 702-837-0685 | |
Randy James Ip, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 | |
Linda Lou Johnson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1501 W Sunset Rd, Henderson, NV 89014 Phone: 725-269-7001 Fax: 725-269-7003 | |
Dr. Daejoon Anh, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2865 Siena Heights Dr Ste 331, Henderson, NV 89052 Phone: 702-407-0110 Fax: 702-407-0133 |